An Introduction to Multiple Sclerosis
Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the CNS and one of the most common causes of neurological disability in adults. It is characterized by a relapsing-remitting clinical course, which progresses to a more chronic progressive phase, although a minority have a progressive course from onset. Numerous disease-modifying therapies (DMTs) have emerged, including oral (fingolimod, dimethyl fumarate, teriflunomide, cladribine, siponimod, ozanimod), injectable (glatiramer acetate, pegylated interferon beta-1a) and intravenous (alemtuzumab, ocrelizumab) options. Challenges include switching therapies in patients who become refractory to initial treatment. MS is also the fastest growing indication for autologous haematopoietic stem cell transplantation in Europe, with a growing body of evidence supporting its use in highly active relapsing-remitting MS that does not respond to DMTs.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Multiple Sclerosis Content
Updates in Paediatric Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
touchREVIEWS in Neurology. 2023;19(1):Online ahead of journal publication
Acute disseminated encephalomyelitis (ADEM), first characterized in 1931,1 is a non-specific clinical syndrome of polyfocal central nervous system (CNS) inflammatory demyelination; it is characterized by encephalopathy and large, poorly demarcated cerebral white matter lesions.2,3 Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), a specific neuronal antibody-mediated disease that can often present as ADEM, was discovered only in the last decade.4 Both […]
Understanding the pathophysiology of multiple sclerosis and the development of new therapies
Prof. Tobias Derfuss reviews the cellular model of disease in multiple sclerosis, and how pathophysiology can offer novel therapeutic targets.
- Explain the cellular model of disease in multiple sclerosis
- Explain how the pathobiology of multiple sclerosis drives the development of disease-modifying therapies
- Summarize the mechanism of action of Bruton’s tyrosine kinase inhibitors and how this may translate into clinical benefits for patients with multiple sclerosis
Multiple sclerosis today: Disease monitoring, biomarkers and family planning
Two experts discuss the role of biomarkers in MS, and the impact of MS on women of childbearing potential
Foreword – touchREVIEWS in Neurology, Volume 18, Issue 2, 2022
Welcome to our new issue of touchREVIEWS in Neurology, which features a wide range of topical articles covering various areas of neurology. We begin with two practice pearls. The first from Garg et al., focusses on the increasingly important subject of social media. Twitter provides a useful platform for clinicians, and this article provides advice on […]
Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis
touchREVIEWS in Neurology. 2022;18(2):117–21 DOI: https://doi.org/10.17925/USN.2022.18.2.117
Over the past two decades, monoclonal antibodies targeting the surface antigen CD20 have emerged as highly effective disease-modifying therapies (DMTs) for multiple sclerosis (MS).1 The major mechanism of action of these therapies is via B-cell depletion, as CD20 is expressed throughout much of the B-cell lineage, including pre-B-cells through memory B-cells. B-cells play multiple roles in […]
Rhonda Voskuhl, ECTRIMS 2022: Pregnancy and breastfeeding in women who are living with multiple sclerosis and planning families
Dr Rhonda Voskuhl is the Director of the UCLA MS Program, holds the Jack H. Skirball Chair in multiple sclerosis, and is a Professor in the UCLA Department of Neurology. She has received national and international awards for her research and has continuous funding for over 20 years. Professor Voskuhl uses a “Bedside to Bench […]
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!